Verastem Appoints José Baselga, M.D., Ph.D., to Scientific Advisory Board

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced today the appointment of José Baselga, M.D., Ph.D., to its Scientific Advisory Board.

“As we advance compounds into the clinic, Dr. Baselga will provide Verastem with an invaluable clinical perspective,” said Robert Weinberg, Ph.D., Verastem co-founder and co-chair of the Scientific Advisory Board.

"Dr. Baselga is a world renowned breast cancer specialist and his expertise will play an integral role in guiding Verastem’s vision of developing revolutionary new treatments for patients afflicted with cancer," said Henri Termeer, Verastem Board of Directors.

Dr. Baselga is the Bruce A. Chabner Chair and chief of the Division of Hematology/Oncology at Massachusetts General Hospital and associate director of the MGH Cancer Center. His research includes the development of novel molecular targeted agents for cancer therapies, with special emphasis on breast cancer. His research in preclinical and early clinical development of therapies has helped develop a number of new targeted cancer-fighting agents. A breast cancer physician and translational researcher, Baselga was chairman of the Medical Oncology Service and director of the Division of Medical Oncology, Hematology and Radiation Oncology at the Vall d'Hebron Institute of Oncology in Barcelona, Spain before moving to Boston in 2010. He also completed a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center where he remained as a faculty member of the Breast Medicine Service until returning to Spain in 1996. Dr. Baselga has published more than 250 peer-reviewed articles and over 400 abstracts and book chapters in his career. Dr. Baselga was previously the president of the European Society of Medical Oncology, served on the board of directors of the American Society of Clinical Oncology (ASCO) and is currently a member of the board of directors of the American Association for Cancer Research (AACR).

“I am honored to join such a talented and highly esteemed scientific team and believe in the potential of Verastem’s technology targeting cancer stem cells to develop much needed novel therapies for cancer patients,” said Dr. Baselga.

“Dr. Baselga’s expertise in translational medicine will guide us as we develop novel therapies to kill cancer stem cells,” said Christoph Westphal, M.D., Ph.D., Chairman of Verastem.

About Verastem, Inc.

Verastem, Inc. is a private biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. Verastem was founded by Rich Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric Lander, Robert Weinberg and Christoph Westphal. Verastem is backed by Advanced Technology Ventures, Astellas Venture Management, Bessemer Venture Partners, Cardinal Partners, Longwood Founders Fund and MPM Capital. For more information, please visit www.verastem.com.



CONTACT:

Weber Shandwick
Lacy Roosevelt, 617-520-7052
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Stem Cells  Health  Biotechnology  Oncology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.